Prediction and Optimization of Nav1.7 Sodium Channel Inhibitors Based on Machine Learning and Simulated Annealing

被引:17
|
作者
Kong, Weikaixin [3 ]
Tu, Xinyu [3 ]
Huang, Weiran [3 ]
Yang, Yang [5 ]
Xie, Zhengwei [1 ,2 ]
Huang, Zhuo [3 ,4 ]
机构
[1] Peking Univ, Int Canc Inst, Sch Basic Med Sci, Hlth Sci Ctr, Beijing 100191, Peoples R China
[2] Peking Univ, Dept Pharmacol, Sch Basic Med Sci, Hlth Sci Ctr, Beijing 100191, Peoples R China
[3] Peking Univ, Dept Mol & Cellular Pharmacol, Sch Pharmaceut Sci, Hlth Sci Ctr, Beijing 100191, Peoples R China
[4] Peking Univ, Dept Mol & Cellular Pharmacol, State Key Lab Nat & Biomimet Drugs, Sch Pharmaceut Sci,Hlth Sci Ctr, Beijing 100191, Peoples R China
[5] Purdue Univ, Coll Pharm, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA
基金
中国国家自然科学基金; 北京市自然科学基金;
关键词
PAIN; CLASSIFICATION; REGRESSION; MUTATIONS; SCN9A; ALGORITHM; DISCOVERY; MODELS; TOOL;
D O I
10.1021/acs.jcim.9b01180
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Although the Na(v)1.7 sodium channel is a promising drug target for pain, traditional screening strategies for discovery of Na(v)1.7 inhibitors are very painstaking and time-consuming. Herein, we aimed to build machine learning models for screening and design of potent and effective Na(v)1.7 sodium channel inhibitors. We customized the imbalanced data set from ChEMBL and BindingDB to train and filter the best classification model. Then, the whole-cell voltage-clamp was employed to validate the inhibitors. We assembled a molecular group optimization method by combining the Grammar Variational Autoencoder, classification model, and simulated annealing. We found that the RF-CDK model (random forest + CDK fingerprint) performs best in the imbalanced data set. Of the three compounds that may have inhibitory effects, nortriptyline has been experimentally verified. In the molecule optimization process, 40 molecules located in the applicability domain of RF-CDK were used as a starting point, among which 34 molecules evolved to molecules with greater molecular scores (MS). The molecule with the highest MS was derived from CHEMBL232524S. The model and method we developed for Na(v)1.7 inhibitors are also applicable to other targets.
引用
收藏
页码:2739 / 2753
页数:15
相关论文
共 50 条
  • [21] Naphthylisoquinoline alkaloids, a new structural template inhibitor of Nav1.7 sodium channel
    Qiao-qiao Wang
    Long Wang
    Wen-bo Zhang
    Chun-ping Tang
    Xue-qin Chen
    Yue-ming Zheng
    Sheng Yao
    Zhao-bing Gao
    Yang Ye
    Acta Pharmacologica Sinica, 2023, 44 : 1768 - 1776
  • [22] β1 subunit stabilises sodium channel Nav1.7 against mechanical stress
    Koerner, Jannis
    Meents, Jannis
    Machtens, Jan-Philipp
    Lampert, Angelika
    JOURNAL OF PHYSIOLOGY-LONDON, 2018, 596 (12): : 2433 - 2445
  • [23] Loss-of-function mutations in sodium channel Nav1.7 cause anosmia
    Jan Weiss
    Martina Pyrski
    Eric Jacobi
    Bernd Bufe
    Vivienne Willnecker
    Bernhard Schick
    Philippe Zizzari
    Samuel J. Gossage
    Charles A. Greer
    Trese Leinders-Zufall
    C. Geoffrey Woods
    John N. Wood
    Frank Zufall
    Nature, 2011, 472 : 186 - 190
  • [24] A central mechanism of analgesia in mice and humans lacking the sodium channel NaV1.7
    MacDonald, Donald Iain
    Sikandar, Shafaq
    Weiss, Jan
    Pyrski, Martina
    Luiz, Ana P.
    Millet, Queensta
    Emery, Edward C.
    Mancini, Flavia
    Iannetti, Gian D.
    Alles, Sascha R. A.
    Arcangeletti, Manuel
    Zhao, Jing
    Cox, James J.
    Brownstone, Robert M.
    Zufall, Frank
    Wood, John N.
    NEURON, 2021, 109 (09) : 1497 - +
  • [25] Regulation of the voltage-gated sodium channel Nav1.7 current in vitro
    Laedermann, Cedric
    Decosterd, Isabelle
    Abriel, Hugues
    SWISS MEDICAL WEEKLY, 2008, 138 (41-42) : 3S - 4S
  • [26] Structure-based drug discovery in a sodium channel: Discovery of chromane arylsulfonamide Nav1.7 inhibitors for the treatment of chronic pain
    McKerrall, Steven
    Bergeron, Philippe
    Safina, Brian
    Ortwine, Daniel
    Shields, Shannon
    Deng, Lunbin
    Hackos, David
    Chen, Jun
    Pang, Jodie
    Chang, Jae
    Lai, Kwong
    Liu, Wenfeng
    Liu, Zhiguo
    Dehnhardt, Christoph
    Johnson, J. P.
    Bankar, Girish
    Cohen, Charles
    Sutherlin, Daniel
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [27] Influence of combined voltage-gated sodium channel NaV1.7 and NaV1.8 inhibitors on cough in a guinea pig model
    Brozmanova, Mariana
    Buday, Tomas
    Jakusova, Janka
    Melegova, Jana
    Plevkova, Jana
    RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 2023, 312
  • [28] Tramadol as a Voltage-Gated Sodium Channel Blocker of Peripheral Sodium Channels Nav1.7 and Nav1.5
    Bok, Chan-Su
    Kim, Ryeong-Eun
    Cho, Yong-Yeon
    Choi, Jin-Sung
    BIOMOLECULES & THERAPEUTICS, 2023, 31 (02) : 168 - 175
  • [29] Optimization of a heteroaryl sulfonamide series of potent, selective and efficacious Nav1.7 inhibitors
    Weiss, Matthew
    Boezio, Alessandro
    Butler, John
    Dineen, Thomas
    Graceffa, Russell
    Kreiman, Charles
    Kornecook, Thomas
    La, Daniel
    Marx, Isaac
    Milgram, Benjamin
    Sparling, Brian
    Moyer, Bryan
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [30] Discovery of morpholine-based aryl sulfonamides as Nav1.7 inhibitors
    Wu, Yong-Jin
    Guernon, Jason
    McClure, Andrea
    Venables, Brian
    Rajamani, Ramkumar
    Robbins, Kevin J.
    Knox, Ronald J.
    Matchett, Michele
    Pieschl, Rick L.
    Herrington, James
    Bristow, Linda J.
    Meanwell, Nicholas A.
    Olson, Richard
    Thompson, Lorin A.
    Dzierba, Carolyn
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (05) : 958 - 962